Science sourced worldwide
LianBio collaborates with world class partners, selecting programs with strong scientific basis and clinical data resulting in a broad and validated late-stage pipeline with first-in-class profile as well as other high potential candidates
Global Clinical Trials Status
Expected China Clinical Trials Status Upon Initiation
Cardiorenal
Pre-clinical
Phase 1/1B
Phase 2
Phase 3
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Non-obstructive Hypertrophic Cardiomyopathy (nHCM)
Precision Diastolic Disease (HFpEF)
Oncology
First-line Cholangiocarcinoma (1LCCA)
Second-line Cholangiocarcinoma (2LCCA)*
Urothelial Carcinoma – Adjuvant*
Gastric Cancer
Other FGFR-driven Tumors
*LianBio will pursue approval in ex-China LianBio Territories via CPP (i.e. clinical trial waivers with regulatory submission post US FDA approval).
SHP2 Inhibitor for RTK Cancers
Respiratory
Pre-clinical
Phase 1/1B
Phase 2
Phase 3
